The US Food and Drug Administration (FDA) has approved Galderma's monoclonal antibody, Nemluvio (nemolizumab), for individuals aged 12 years and over with moderate-to-severe atopic dermatitis.

Dermatology specialist Galderma has claimed a second FDA approval for IL-31 inhibitor Nemluvio, adding atopic dermatitis to its label. Nemluvio (nemolizumab) – which was approved by the FDA in ...

Dermatology specialist Galderma has FDA approval for prurigo nodularis treatment Nemluvio, one of two new drugs that it thinks will deliver blockbuster sales. The US regulator cleared the IL-31 ...

Nemluvio is the first approved monoclonal antibody that specifically targets IL-31 receptor alpha, inhibiting the signaling of IL-31. 8 IL-31 is a neuroimmune cytokine that drives itch and is ...

Nemluvio (nemolizumab-ilto) Interleukin-31 receptor antagonist Treatment of adults and pediatric patients 12 years of age and older with moderate to severe atopic dermatitis in combination with ...

Dr. Navin Arora of Borealis Dermatology discusses new injectables EBGLYSS and Nemluvio for eczema patients as well as innovations in phototherapy. There are several new treatments for chronic ...

ZUG, Switzerland, December 13, 2024--Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio® (nemolizumab) for the treatment of ...

Galderma (SWX:GALD) today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Nemluvio ® (nemolizumab) for the treatment of patients 12 years and older with ...

IL-31 is a neuroimmune cytokine that drives itch and is involved in inflammation and epidermal dysregulation in atopic dermatitis 2,9-11 This approval follows Nemluvio’s recent approval for the ...